LIVE WEBINAR: Thursday, March 18, 2021, 5:00 PM – 6:00 PM Eastern Time

Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care

A 2-Part Complimentary NCPD Webinar Series

Part 2 — HER2-Positive Breast Cancer

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, March 18th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET


Jamie Carroll, APRN, MSN, CNP
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Santa Monica, California

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Puma Biotechnology Inc.

Thursday, March 18, 2021
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • Discussion of the clinical variables that guide the selection of specific therapeutic regimens for patients with HER2-overexpressing breast cancer (BC)
  • Evaluation of the available data with existing HER2-targeted therapies and integration of recently approved agents into current treatment algorithms
  • Recognition and management of the common and rare side effects associated with FDA-approved HER2-directed therapies in the care of patients with BC

Target Audience
This activity has been designed to meet the educational needs of registered nurses, nurse practitioners and clinical nurse specialists involved in the treatment of HER2-positive breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and use this information to counsel patients regarding personalized treatment decision-making.
  • Apply available research evidence to individualize the selection and administration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
  • Appraise available research data leading to the recent FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer, and identify patients who are appropriate candidates for treatment with this drug.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive breast cancer, and optimally integrate this novel regimen into treatment algorithms.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with approved anti-HER2 agents, and devise supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
Accreditation Statements
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Puma Biotechnology Inc.